Détail de l'auteur
Auteur Barohn RJ |
Documents disponibles écrits par cet auteur (84)



![]()
Minimal manifestation status and prednisone withdrawal in the MGTX trial
Lee I, Kuo HC, Aban IB, et al.
Neurology, 2020
Revue : Neurology Titre : Minimal manifestation status and prednisone withdrawal in the MGTX trial Type de document : Article Auteurs : Lee I ; Kuo HC ; Aban IB ; Cutter GR ; McPherson T ; Kaminski HJ ; Sussman J ; Strobel P ; Oger J ; Cea G ; Heckmann JM ; Evoli A ; Nix W ; Ciafaloni E ; Antonini G ; Witoonpanich R ; King JO ; Beydoun SR ; Chalk CH ; Barboi AC ; Amato AA ; Shaibani AI ; Katirji B ; Lecky BRF ; Buckley C ; Vincent A ; Dias-Tosta E ; Yoshikawa H ; Waddington-Cruz M ; Pulley MT ; Rivner MH ; Kostera-Pruszczyk A ; Pascuzzi RM ; Jackson CE ; Verschuuren JJG ; Massey JM ; Kissel JT ; Werneck LC ; Benatar M ; Barohn RJ ; Tandan R ; Mozaffar T ; Conwit R ; Minisman G ; Sonett JR ; Wolfe GI Editeur : United States Année de publication : 07/2020 Langues : Anglais (eng) Lien associé : NCT00294658 Pubmed / DOI : Pubmed : 32611638 / DOI : 10.1212/WNL.0000000000010031
N° Profil MNM : 2020062 En ligne : http://www.ncbi.nlm.nih.gov/pubmed/32611638 Avis des lecteurs Aucun avis, ajoutez le vôtre !
(mauvais) 15 (excellent)
![]()
Guidelines on clinical presentation and management of non-dystrophic myotonias
Stunnenberg B, LoRusso S, Arnold WD, et al.
Muscle & Nerve, 2020
Revue : Muscle & Nerve Titre : Guidelines on clinical presentation and management of non-dystrophic myotonias Type de document : Article Auteurs : Stunnenberg B, Auteur ; LoRusso S ; Arnold WD ; Barohn RJ ; Cannon SC ; Fontaine B ; Griggs RC ; Hanna MG ; Matthews E ; Meola G ; Sansone VA ; Trivedi JR ; van Engelen B ; Vicart S ; Statland JM Editeur : United States Année de publication : 04/2020 Langues : Anglais (eng) Pubmed / DOI : Pubmed : 32270509 / DOI : 10.1002/mus.26887
N° Profil MNM : 2020041 En ligne : http://www.ncbi.nlm.nih.gov/pubmed/32270509 Avis des lecteurs Aucun avis, ajoutez le vôtre !
(mauvais) 15 (excellent)
![]()
Methotrexate Polyglutamation in a Myasthenia Gravis Clinical Trial
Pasnoor M, Heim AJ, Herbelin L, et al.
Kansas journal of medicine, 2020, 13, suppl 2, p 10
Revue : Kansas journal of medicine, 13, suppl 2 Titre : Methotrexate Polyglutamation in a Myasthenia Gravis Clinical Trial Type de document : Article Auteurs : Pasnoor M, Auteur ; Heim AJ ; Herbelin L ; Statland J ; Dimachkie MM ; Becker M ; Barohn RJ Année de publication : 02/2020 Pages : p 10 Langues : Anglais (eng) Lien associé : Texte complet disponible sur le site PMC Pubmed / DOI : Pubmed : 32256969 N° Profil MNM : 2020041 En ligne : http://www.ncbi.nlm.nih.gov/pubmed/32256969 Avis des lecteurs Aucun avis, ajoutez le vôtre !
(mauvais) 15 (excellent)
![]()
Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America
Green JD, Barohn RJ, Bartoccion E, et al.
BMJ Open, 2020, 10, 9
Revue : BMJ Open, 10, 9 Titre : Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America Type de document : Article Auteurs : Green JD ; Barohn RJ ; Bartoccion E ; Benatar M ; Blackmore D ; Chaudhry V ; Chopra M ; Corse A ; Dimachkie MM ; Evoli A ; Florence J ; Freimer M ; Howard JF ; Jiwa T ; Kaminski HJ ; Kissel JT ; Koopman WJ ; Lipscomb B ; Maestri M ; Marino M ; Massey JM ; McVey A ; Mezei MM ; Muppidi S ; Nicolle MW ; Oger J ; Pascuzzi RM ; Pasnoor M ; Pestronk A ; Provenzano C ; Ricciardi R ; Richman DP ; Rowin J ; Sanders DB ; Siddiqi Z ; Soloway A ; Wolfe GI ; Wulf C ; Drachman DB ; Traynor BJ Année de publication : 2020 Langues : Anglais (eng) Pubmed / DOI : Pubmed : 32948566 / DOI : 10.1136/bmjopen-2020-037909
N° Profil MNM : 2020092 En ligne : http://www.ncbi.nlm.nih.gov/pubmed/32948566 Avis des lecteurs Aucun avis, ajoutez le vôtre !
(mauvais) 15 (excellent)
![]()
Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy
Campbell C, Barohn RJ, Bertini E, et al.
Journal of comparative effectiveness research, 2020
Revue : Journal of comparative effectiveness research Titre : Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy Type de document : Article Auteurs : Campbell C ; Barohn RJ ; Bertini E ; Chabrol B ; Comi GP ; Darras BT ; Finkel RS ; Flanigan KM ; Goemans N ; Iannaccone ST ; Jones KJ ; Kirschner J ; Mah JK ; Mathews KD ; McDonald CM ; Mercuri E ; Nevo Y ; Pereon Y ; Renfroe JB ; Ryan MM ; Sampson JB ; Schara U ; Sejersen T ; Selby K ; Tulinius M ; Vilchez JJ ; Voit T ; Wei LJ ; Wong BL ; Elfring G ; Souza M ; McIntosh J ; Trifillis P ; Peltz SW ; Muntoni F Editeur : England Année de publication : 2020 Langues : Anglais (eng) Lien associé : NCT00592553
NCT01826487Pubmed / DOI : Pubmed : 32851872 / DOI : 10.2217/cer-2020-0095
N° Profil MNM : 2020091 En ligne : http://www.ncbi.nlm.nih.gov/pubmed/32851872 Avis des lecteurs Aucun avis, ajoutez le vôtre !
(mauvais) 15 (excellent)
![]()
The history of acetylcholinesterase inhibitors in the treatment of myasthenia gravis
Katz NK, Barohn RJ
Neuropharmacology, 2020
Permalink![]()
MRI Correlates with Electrical Impedance Myography in Facioscapulohumeral Muscular Dystrophy
Hamel J, Lee P, Glenn MD, et al.
Muscle & Nerve, 2019
Permalink![]()
Immunosuppressive and Immunomodulatory Therapies for Neuromuscular Diseases Part I: Traditional Agents
Farmakidis C, Dimachkie M, Pasnoor M, et al.
Muscle & Nerve, 2019
Permalink![]()
Immunosuppressive and Immunomodulatory Therapies for Neuromuscular Diseases Part II: New and Novel Agents.
Farmakidis C, Dimachkie M, Pasnoor M, et al.
Muscle & Nerve, 2019
Permalink![]()
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial
Hanna MG, Badrising UA, Benveniste O, et al.
The Lancet. Neurology, 2019, 18, 9, p 834
Permalink![]()
Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis
Clifford KM, Clifford KM, Hobson-Webb LD, et al.
Muscle & Nerve, 2019, 59, 4, p 404
Permalink![]()
Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naive and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study
Pena LDM, Barohn RJ, Byrne BJ, et al.
Neuromuscular disorders : NMD, 2019, 29, 3, p 167
Permalink![]()
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial
Wolfe GI, Kaminski HJ, Aban IB, et al.
The Lancet. Neurology, 2019, 18, 3, p 259
Permalink![]()
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis
Muppidi S, Utsugisawa K, Benatar M, et al.
Muscle & Nerve, 2019
Permalink![]()
Inclusion Body Myositis: Update on Pathogenesis and Treatment
Naddaf E, Barohn RJ, Dimachkie MM
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2018, 15, 4, p 995
Permalink![]()
Congenital Myasthenic Syndromes: a Clinical and Treatment Approach
Farmakidis C, Farmakidis C, Pasnoor M, et al.
Current treatment options in neurology, 2018, 20, 9
Permalink![]()
Diagnosis of Myasthenia Gravis
Pasnoor M, Dimachkie MM, Farmakidis C, et al.
Neurologic clinics, 2018, 36, 2, p 261
Permalink![]()
Fifty Key Publications on Myasthenia Gravis and Related Disorders
Dimachkie MM, Barohn RJ
Neurologic clinics, 2018, 36, 2, p 13
Permalink![]()
Measuring Clinical Treatment Response in Myasthenia Gravis
Barnett C, Herbelin L, Dimachkie MM, et al.
Neurologic clinics, 2018, 36, 2, p 339
Permalink![]()
Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies
Rivner MH, Pasnoor M, Dimachkie MM, et al.
Neurologic clinics, 2018, 36, 2, p 293
Permalink![]()
Treatment of Myasthenia Gravis
Farmakidis C, Pasnoor M, Dimachkie MM, et al.
Neurologic clinics, 2018, 36, 2, p 311
Permalink![]()
A checklist for clinical trials in rare disease: obstacles and anticipatory actions-lessons learned from the FOR-DMD trial
Crow RA, Hart KA, McDermott MP, et al.
Trials, 2018, 19, 1
Permalink![]()
2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups
Lundberg IE, Tjärnlund A, Bottai M, et al.
Annals of the rheumatic diseases, 2017, 76, 12, p 1955
Permalink![]()
Developing standardized corticosteroid treatment for Duchenne muscular dystrophy
Guglieri M, Bushby K, McDermott MP, et al.
Contemporary clinical trials, 2017, 58, p 34
Permalink![]()
Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing
Vander Heiden JA, Stathopoulos P, Zhou JQ, et al.
Journal of immunology (Baltimore, Md. : 1950), 2017, 198, 4, p 1460
Permalink